Skip to main content

Table 2 Baseline patient, tumor, and treatment characteristics for all patients (n = 115) and broken down by patients did or did not experience SL

From: Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Characteristic

Total (N = 115)

SL (N = 63)

No SL (N = 52)

P value

Age at diagnosis, years, Median (IQR)

63.00 (59.00–67.00)

63.00 (60.00–67.00)

62.50 (55.50–67.00)

0.362

Sex

 Male

107 (92.2%)

59 (51.3%)

48 (41.7%)

 

 Female

8 (7.0%)

4 (3.5%)

4 (3.5%)

0.778

ECOG performance status

 0–1

84 (73.0%)

44 (38.3%)

40 (34.8%)

 

 2

31 (27.0%)

19 (16.5%)

12 (10.4%)

0.394

Smoking pack-years

 

 ≥ 10

80

45

35

 

 0–10

4

3

1

 

 0

24

12

12

 

 Unkown

7

3

4

0.717

Histology

 Squamous carcinoma

78 (67.8%)

49 (42.2%)

35 (30.4%)

 

 Adenocarcinoma

34 (29.6%)

19 (16.5%)

15 (13.0%)

 

 Others

3 (2.6%)

1 (0.9%)

2 (1.7%)

0.683

cT stage (AJCC 8th ed)

 T1

14 (12.2%)

8 (7.0%)

6 (5.2%)

 

 T2

31 (26.7%)

20 (17.2%)

11 (9.57%)

 

 T3

27 (23.5%)

12 (10.4%)

15 (13.0%)

 

 T4

43 (37.4%)

23 (20.0%)

20 (17.4%)

0.492

cN stage

 N1

6 (5.2%)

2 (1.7%)

4 (3.5%)

 

 N2

73 (63.5%)

39 (33.9%)

34 (29.6%)

 

 N3

36 (31.3%)

22 (19.1%)

14 (12.2%)

0.417

Stage

 IIIA

33 (28.7%)

18 (15.7%)

15 (13.0%)

 

 IIIB

61 (53.0%)

33 (28.7%)

28 (24.3%)

 

 IIIC

21 (18.3%)

12 (10.4%)

9 (7.8%)

0.971

TLCs, cells/μL (median, IQR)

 Baseline

1600 (1400–2000)

1600 (1300–1900)

1800 (1400–2200)

0.037

 Pre-RT

1800 (1400–2100)

1600 (1280–1900)

1965 (1700–2252)

<  0.001

 TLC nadir during the course of RT

500 (380–700)

390 (300–470)

700 (600–830)

<  0.001

 1 month after RT

915 (700–1100)

800 (598–1100)

995 (882–1232)

0.004

 2 month after RT

900 (700–1100)

740 (600–982)

1000 (810–1195)

<  0.001

Tumor volume, cm3 (median, IQR)

 

 GTV

56.85 (32.47–129.35)

87.69 (45.58–144.92)

43.40 (21.84–95.52)

0.006

 PTV

146.03 (74.20–247.39)

160.95 (80.69–258.92)

124.82 (71.13–224.05)

0.192

EQD2 (Gy or Gy[RBE]) (median, IQR)

64.00 (60.00–65.00)

62.87 (60.00–65.10)

65.00 (60.00–65.00)

0.755

BED (Gy)

76.80 (72.00–78.00)

75.44 (72.00–78.13)

78 (72–78)

0.768

Fractions, number (median, IQR)

25 (20–30)

25 (25–30)

25 (20–30)

0.141

OTT, days (median, IQR)

39 (31–43)

39 (33–43)

35 (29–43)

0.281

Key mean normal tissue doses, cGy (median, IQR)

 Mean lung dose

1275 (1078–1454)

1354.90 (1146.00–1480.00)

1165 (990–1386)

0.007

 Mean heart dose

601 (420–1261.50)

886 (439.00–1502.25)

518 (384–936.90)

0.041

Radiation technique

 3D conformal

28 (24.3%)

16 (13.9%)

12 (10.4%)

 

 Intensity modulated

37 (32.2%)

19 (16.5%)

18 (15.7%)

 

 Helical Tomotherapy

50 (43.5%)

28 (24.3%)

22 (19.1%)

0.874

Concurrent chemoradiation (sequential)

 Yes

31 (27.0%)

15 (12.9%)

16 (13.9%)

 

 No

84 (73.0%)

48 (41.7%)

36 (31.3%)

0.403

Induction chemotherapy

 Yes

91 (79.1%)

54 (47.0%)

37 (32.2%)

 

 No

24 (20.9%)

9 (7.8%)

15 (13.0%)

0.056

Adjuvant chemotherapy

 Yes

61 (53.0%)

31 (27.0%)

30 (26.1%)

 

 No

54 (47.0%)

32 (27.8%)

22 (19.1%)

0.364

  1. Abbreviations: SL severe lymphopenia, IQR interquartile range, ECOG Eastern Cooperative Oncology Group, AJCC American Joint Committee on Cancer, TLCs total peripheral lymphocyte counts, GTV gross tumor volume, PTV planning target volume, EQD2 equivalents (relative biological equivalents), BED biological effective dose, OTT overall treatment time